President Trump's rescheduling order directing federal agencies to reschedule marijuana has triggered a wave of merger and acquisition activity as cannabis companies race to position themselves for a potentially transformed regulatory landscape.
The December 18 order instructed the Department of Justice and HHS to complete the rescheduling process, which would move cannabis from Schedule I to Schedule III of the Controlled Substances Act.
The M&A Rush
Within weeks of the announcement, multiple deals were announced or accelerated:
Cannabis companies that had been in preliminary acquisition talks moved to finalize agreements. Private equity firms that had stayed on the sidelines began actively pursuing targets. And publicly traded operators saw their stock prices surge, providing currency for stock-based acquisitions.
"This is just the beginning," one cannabis industry analyst said. "We expect to see a sustained increase in strategic partnerships as companies position themselves for the anticipated legal changes."
What Rescheduling Means
Moving cannabis to Schedule III would not legalize the drug federally, but it would have significant practical effects:
- Cannabis businesses could deduct normal business expenses on federal taxes (currently prohibited under Section 280E)
- Banks and financial institutions would face reduced risk in serving the industry
- Research restrictions would ease substantially
These changes could fundamentally alter the economics of cannabis companies, making previously unprofitable operations viable and well-capitalized firms more attractive acquisition targets.
Consolidation Concerns
Not everyone views the M&A surge positively. Some industry observers warn that rapid consolidation could reduce competition, potentially leading to higher prices and fewer choices for consumers.
Small and minority-owned operators, who have struggled to compete with better-funded rivals, may find themselves acquisition targets rather than independent competitors in the new landscape.
Timeline Uncertain
The rescheduling process typically takes 12 to 18 months, though the administration has signaled it wants to move faster. Companies making deals now are betting that the change will ultimately happen—a reasonable assumption, but not a certainty.
This article is based on original reporting by MJBizDaily.
